Valuation: PAVmed Inc.

Market Cap 33.43M 29.43M 27.15M 25.39M 47.58M 3.15B 48.46M 326M 126M 1.55B 126M 123M 5.41B P/E 2026 *
-1.49x
P/E 2027 * -3.65x
Enterprise Value 33.43M 29.43M 27.15M 25.39M 47.58M 3.15B 48.46M 326M 126M 1.55B 126M 123M 5.41B EV / Sales 2026 *
98.3x
EV / Sales 2027 * 51.2x
Free-Float
56.63%
Yield 2026 *
-
Yield 2027 * -
1 day-0.22%
1 week-6.60%
Current month-24.66%
1 month-26.92%
3 months-49.24%
6 months-45.86%
Current year-29.50%
1 week 4.42
Extreme 4.4213
5.68
1 month 3.85
Extreme 3.85
6.5
Current year 3.85
Extreme 3.85
28.44
1 year 3.85
Extreme 3.85
28.44
3 years 3.85
Extreme 3.85
270
5 years 3.85
Extreme 3.85
4,365
10 years 3.85
Extreme 3.85
6,858
Manager TitleAgeSince
Compliance Officer 62 2023-03-31
Chief Executive Officer 60 2014-06-25
Director of Finance/CFO 69 2017-03-20
Director TitleAgeSince
Director/Board Member 60 2014-09-30
Chairman 60 2014-06-25
Director/Board Member 71 2014-12-31
Date Insider Type Main position Quantity % Market Cap.
04-01Free

General Counsel

110,000 1.7233%
04-01Free

Chief Executive Officer

350,000 5.4832%
04-01Free

Chief Operating Officer

110,000 1.7233%
Change 5-day change 1-year change 3-year change Capi.($)
-0.22%-6.60%-74.38%-97.27% 33.5M
+4.87%+6.61%+21.72%-6.11% 174B
-0.33%-0.09%-23.18%+22.79% 143B
+5.53%+6.25%-4.36%-20.70% 127B
-2.50%-1.09%-57.30%-17.62% 67.78B
+3.12%+3.44%+18.21%-0.75% 50.07B
-0.84%-1.21%-27.01%-33.20% 43.84B
+3.92%+5.87%+11.89%+10.22% 35.78B
+3.35%+3.41%+6.45%+42.08% 35.07B
+1.82%+6.10%-9.86%-18.72% 28.99B
Average +1.87%-0.09%-13.78%-11.93% 70.54B
Weighted average by Cap. +2.50%+0.76%-5.48%-2.59%

Financials

2026 *2027 *
Net sales 340K 299K 276K 258K 484K 32.05M 493K 3.32M 1.29M 15.81M 1.28M 1.25M 55M 652K 574K 530K 496K 929K 61.5M 946K 6.37M 2.47M 30.34M 2.45M 2.4M 106M
Net income -20.96M -18.45M -17.02M -15.92M -29.83M -1.98B -30.38M -205M -79.23M -975M -78.69M -76.99M -3.39B -18.18M -16M -14.76M -13.81M -25.87M -1.71B -26.35M -177M -68.72M -845M -68.25M -66.77M -2.94B
Net Debt - -
Logo PAVmed Inc.
PAVmed Inc. is a multi-product, commercial-stage medical technology company. The Company operates in the medical devices, diagnostics, and digital health sectors. Its subsidiary includes Lucid Diagnostics Inc., which is a commercial-stage cancer prevention medical diagnostics company that markets the EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device for early detection of esophageal precancer to prevent esophageal cancer deaths. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells. EsoGuard is a bisulfite-converted next-generation sequencing (NGS) DNA assay performed on surface esophageal cells collected with EsoCheck. Its other subsidiary, Veris Health Inc., is a digital health company focused on enhanced personalized cancer care through remote patient monitoring using implantable biologic sensors with wireless communication along with a custom suite of connected external devices.
Employees
41
Date Price Change Volume
26-06-24 US$4.670 -0.22% 3,591
26-06-23 US$4.680 -4.68% 7,566
26-06-22 US$4.910 -4.84% 14,980
26-06-18 US$5.160 +3.20% 208,426
26-06-17 US$5.000 +0.30% 4,739
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
4.670USD
Average target price
36.00USD
Spread / Average Target
+670.89%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PAVM Stock